Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$17.24 +2.3%	$12.81	$7.75 ▼ $19.93	$131.68M	0.55	26,228 shs	53,532 shs
GLSI Greenwich LifeSciences	$9.20	$9.63	$8.06 ▼ $18.75	$122.99M	1.69	46,655 shs	27,956 shs
IRWD Ironwood Pharmaceuticals	$0.67 +8.1%	$0.73	$0.53 ▼ $7.11	$108.42M	0.24	2.61 million shs	1.79 million shs
OMED OncoMed Pharmaceuticals		$0.89	$0.55 ▼ $3.35	$34.43M	1.86	768,904 shs	1,201 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	+3.76%	+25.56%	+59.11%	+9.49%
GLSI Greenwich LifeSciences	0.00%	-4.76%	-5.54%	-24.65%	-37.67%
IRWD Ironwood Pharmaceuticals	0.00%	+1.87%	+8.77%	-59.74%	-89.37%
OMED OncoMed Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	4.0767 of 5 stars	3.3	5.0	0.0	4.7	1.9	0.8	0.0
GLSI Greenwich LifeSciences	2.2609 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.0
IRWD Ironwood Pharmaceuticals	4.6611 of 5 stars	4.1	3.0	0.0	3.4	3.8	0.8	1.9
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	91.42% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	323.91% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	613.93% Upside
OMED OncoMed Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMED, ASMB, IRWD, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70
4/14/2025	IRWD Ironwood Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$3.00 ➝ $1.00
4/14/2025	IRWD Ironwood Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/25/2025	ASMB Assembly Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
3/24/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$32.15M	4.10	N/A	N/A	$7.50 per share	2.30
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.52 per share	N/A
IRWD Ironwood Pharmaceuticals	$317.68M	0.34	N/A	N/A	($2.21) per share	-0.30
OMED OncoMed Pharmaceuticals	$44.42M	0.00	N/A	N/A	$1.25 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$61.23M	-$6.23	N/A	N/A	N/A	-144.05%	-121.46%	-34.56%	8/6/2025 (Estimated)
GLSI Greenwich LifeSciences	-$8.89M	-$1.26	N/A	N/A	N/A	N/A	-185.12%	-164.27%	8/12/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	-$1.00B	-$0.20	N/A	2.68	N/A	-0.65%	-0.96%	0.74%	8/6/2025 (Estimated)
OMED OncoMed Pharmaceuticals	-$8.10M	-$0.16	N/A	N/A	N/A	-18.24%	-13.14%	-7.73%	N/A

Latest OMED, ASMB, IRWD, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/20/2025	Q4 2024	ASMB Assembly Biosciences	-$1.75	-$1.57	+$0.18	-$1.57	$7.05 million	$7.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	2.36	2.36
GLSI Greenwich LifeSciences	N/A	6.91	6.91
IRWD Ironwood Pharmaceuticals	N/A	3.62	3.62
OMED OncoMed Pharmaceuticals	N/A	5.04	5.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
GLSI Greenwich LifeSciences	4.16%
IRWD Ironwood Pharmaceuticals	N/A
OMED OncoMed Pharmaceuticals	45.16%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
GLSI Greenwich LifeSciences	51.67%
IRWD Ironwood Pharmaceuticals	12.70%
OMED OncoMed Pharmaceuticals	20.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.64 million	6.03 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.35 million	Not Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	139.38 million	Optionable
OMED OncoMed Pharmaceuticals	22	38.69 million	N/A	Optionable

OMED, ASMB, IRWD, and GLSI Headlines

Recent News About These Companies

Tenaya Therapeutics appoints new interim principal accounting officer

February 8, 2025 | msn.com

Stem Cell Treatments for Cancer Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032

April 18, 2024 | taiwannews.com.tw

Carboplatin Price of 38 Brands

August 8, 2023 | medindia.net

Fluorouracil Price of 38 Brands

July 9, 2023 | medindia.net

Ionis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, Predictions

June 8, 2023 | benzinga.com

Commission’s new strategy aims to rewrite pharma rules

May 16, 2023 | politico.eu

Dacarbazine Price of 18 Brands

May 9, 2023 | medindia.net

Bispecific Antibody Market Size | Statistics By 2031

April 7, 2023 | marketwatch.com

2023, Bispecific Antibody Market is thriving worldwide by 2029

March 30, 2023 | marketwatch.com

2023-2029 Cancer Stem Cell Market Size and Risks Factors Analysis | Survey Report by Absolute Reports

February 28, 2023 | marketwatch.com

Forecast for 2028, Bispecific Antibody Market 2023, Global Industry Trends, Share, Size, Growth, Demand

February 27, 2023 | marketwatch.com

Bispecific Antibody Market : Top Key Players Data with Upcoming Opportunities and Innovations

February 16, 2023 | marketwatch.com

Bispecific Antibody Market Insights-Industry changing aspects, New Technologies and Forecast to 2029

February 4, 2023 | marketwatch.com

Bispecific Antibody Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook Report

January 19, 2023 | marketwatch.com

Bispecific Antibody Market New Innovations and Future Expansion 2022-2028 with Top Countries Data

November 18, 2022 | marketwatch.com

Fallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

November 14, 2022 | finance.yahoo.com

Imugene welcomes drug development, oncology and cell therapy expert to the team

September 7, 2022 | au.investing.com

Shuttle Pharmaceuticals Shares Continue to Surge, Rising 74%

September 1, 2022 | marketwatch.com

Shuttle Pharmaceuticals Shares More Than Triple in Debut

August 31, 2022 | marketwatch.com

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

August 16, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMED, ASMB, IRWD, and GLSI Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$17.24 +0.39 (+2.31%)

Closing price 04:00 PM Eastern

Extended Trading

$17.24 +0.01 (+0.03%)

As of 06:06 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Greenwich LifeSciences NASDAQ:GLSI

$9.20 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$9.19 -0.01 (-0.11%)

As of 04:11 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.67 +0.05 (+8.06%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 0.00 (-0.60%)

As of 07:38 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

OncoMed Pharmaceuticals NASDAQ:OMED

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time